Please select the option that best describes you:
In a patient with early stage HR+ breast cancer who was perimenopausal at diagnosis but intolerant of AI, would you consider extending tamoxifen beyond 10 years?
In the absence of side effects, would you be inclined to continue beyond 10 years as chemoprevention? Would you factor an intermediate/high oncotype RS into your decision?
Answer from: Medical Oncologist at Community Practice
ATLAS and aTTom trial : - 10 years of extended adjuvant Therapy.
In absence of data, I will not extend Adjuvant Therapy.
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
It depends upon the characteristics of primary breast cancer. For example, in the case of multi-node positivity, I would extend the duration to ten years total. In stage IA breast cancers, I generally don't extend the duration of anti-estrogen therapy.
In the case of intermediate or high-risk Oncot...
Comments
Medical Oncologist at Penn State Cancer Institute
In the same vein, how would you counsel patients o...
In the same vein, how would you counsel patients o...
Medical Oncologist at Icahn School of Medicine at Mount Sinai
I would tell her there is no evidence for extendin...
I would tell her there is no evidence for extendin...